Selected article for: "ALT elevation and AST elevation"
Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
    • ID: 9hknw4ws_28
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 3 occurrence resulting in death, prolonged hospitalization, persistent or significant disability or incapacity, which was judged to be causally related to the study intervention, would be reported as a serious adverse event to the Institutional Review Board. Potential adverse events for the study were d.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.19.20038984 doi: medRxiv preprint 1 3 occurrence resulting in death, prolonged hospitalization, persistent or significant disability or incapacity, which was judged to be causally related to the study intervention, would be reported as a serious adverse event to the Institutional Review Board. Potential adverse events for the study were defined as follows (1) anaphylaxis; (2) elevation of ALT or AST to more than 2.5-fold the upper normal limit or elevation of TBIL to more than 1.5-fold the upper normal limit; (3) acute pancreatitis; and (4) diarrhea.

    Search related documents:
    Co phrase search for related documents
    • acute pancreatitis and elevation upper normal limit: 1
    • acute pancreatitis and normal limit: 1, 2, 3, 4, 5
    • acute pancreatitis and study adverse event: 1
    • acute pancreatitis and upper normal limit: 1, 2, 3, 4, 5
    • adverse event and follow define: 1
    • adverse event and normal limit: 1, 2
    • adverse event and study adverse event: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and study intervention: 1, 2, 3, 4, 5
    • adverse event and upper normal limit: 1, 2
    • elevation upper normal limit and normal limit: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • elevation upper normal limit and upper normal limit: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • incapacity significant persistent disability and significant persistent disability: 1
    • normal limit and study adverse event: 1
    • normal limit and study intervention: 1, 2
    • normal limit and upper normal limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • study adverse event and upper normal limit: 1
    • study intervention and upper normal limit: 1, 2